The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere™ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.
Under the agreement, the two organizations aim to advance drug development and discovery projects utilizing the MOS platform, which enables translational research on...
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight the importance of cancer research, to promote scientific collaboration and to reduce the global burden of cancer through improved prevention, early detection, treatment and survivorship strategies.
Launched in 2016, World Cancer Research Day is an international effort now supported by more than...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts...
The University of Texas MD Anderson Cancer Center today launched the James P. Allison Institute, a visionary research and innovation...
A multicenter research team co-led by The University of Texas MD Anderson Cancer Center developed the first drug to treat the uncontrolled...
A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from...